Dosing with recombinant factor viia based on current evidence.

  title={Dosing with recombinant factor viia based on current evidence.},
  author={Ulla Hedner},
  journal={Seminars in hematology},
  volume={41 1 Suppl 1},
Recombinant factor VIIa (rFVIIa; NovoSeven(R), Novo Nordisk, Bagsvaerd, Denmark) induces hemostasis in patients with severe hemophilia and inhibitors, and has been found to control hemorrhage associated with severe trauma and surgery in patients with basically normal hemostatic mechanisms from the start. By enhancing the generation of thrombin on activated platelets, rFVIIa facilitates the formation of a tight, stable fibrin plug that is resistant to premature lysis. Clinical efficacy has been… CONTINUE READING